^
    Back
    Association details:
    Biomarker:BCR-ABL1 T315I
    Cancer:B Acute Lymphoblastic Leukemia
    Regimen: (Venclexta (venetoclax) + Iclusig (ponatinib) + dexamethasone)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2021
    Title:

    Venetoclax-Ponatinib for T315I/Compound-Mutated Ph+Acute Lymphoblastic Leukemia

    Published date:
    11/04/2021
    Excerpt:
    Here, we firstly reported outcome of 19 T315I/compound-mutated relapsed/refractory (R/R) Ph+ ALL patients treated with venetoclax(100mg d1, 200mg d2, 400mg d3-28), ponatinib (45mg d1-28) and dexamethasone (0.15mg/kg d1-21,0.075mg/kg d22-28) (VPD regimen)…After one cycle, 17 patients (89.5%) achieved CR/CRi [13 minimal residual disease (MRD)--negative by flow cytometry;11 major molecular remission (MMR);8 complete molecular remission (CMR)].
    DOI:
    10.1182/blood-2021-152836